Population pharmacokinetics of cyclosporine a based on NONMEM in chinese allogeneic hematopoietic stem cell transplantation recipients

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 4, 2012, Pages 271-278

  Zhou, Hui ^a   Gao, Yan ^a   Cheng, Xiao Liang ^b   Li, Zhong Dong ^a  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cyclosporine A; NONMEM; Population pharmacokinetics

Indexed keywords

ALBUMIN; CORTICOSTEROID; CYCLOSPORIN A; FAMOTIDINE; FLUCONAZOLE; ITRACONAZOLE; METHOTREXATE; METRONIDAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; OMEPRAZOLE; RIFAMPICIN;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BOOTSTRAPPING; CHINESE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEALTH PROGRAM; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOSPORINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS;

EID: 84871287343     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-012-0087-8     Document Type: Article

References (23)

1. Beauchesne PR, Chung NS, Wasan KM (2007) Cyclosporine A: A review of current oral and intravenous delivery systems. Drug Dev Ind Pharm 33(3):211-220
2. Bourgoin H, Paintaud G, Chler M, Lebranchu Y, Autret-Leca E, Le-Guellec C (2005) Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 59(1):18-27
3. Citterio F (2004) Evolution of the therapeutic drug monitoring of cyclosporine. Transpl Proc 36(2 Suppl):420S-425S
4. David-Neto E, Araujo LM, Brito ZM, Alves CF, Lemos FC, Yagyu EM, Nahas WC, Ianhez LE (2002) Sampling strategy to calculate the cyclosporin-A area under the time-concentration curve. Am J Transpl 2(6):546-550
5. del Mar Fernández De Gatta M, Santos-Buelga D, Domínguez-Gil A, García MJ (2002) Immunosuppressive therapy for paediatric transplant patients: Pharmacokinetic considerations. Clin Pharmacokinet 41(2):115-135
6. Du XL, Fu Q (2009) Population pharmacokinetic study of cyclosporine in patients with nephrotic syndrome. J Clin Pharmacol 49(7):782-788
7. Falck P, Midtvedt K, Vân Lê TT, Storehagen L, Holdaas H, Hartmann A, Asberg A (2009) A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients. Clin Pharmacokinet 48(9):615-623
8. Faulds D, Goa KL, Benfield P (1993) Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45(6):953-1040
9. Fukudo M (2007) Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis. Yakugaku Zasshi 127(7):1081-1089
10. Ghalie R, Fitzsimmons WE, Weinstein A, Manson S, Kaizer H (1994) Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation. Ann Pharmacother 28(3):379-383
11. Gibbs MA, Hosea NA (2003) Factors affecting the clinical development of cytochrome P450 3A substrates. Clin Pharmacokinet 42(11):969-984
12. International Neoral Renal Transplantation Study Group (2002) Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transpl 2(2):148-156
13. Jacobson PA, Ng J, Green KG, Rogosheske J, Brundage R (2003) Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl 9(5):304-311
14. Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA, Berkman E, Rabson A (1994) Adjusted-dose continuousinfusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol 68(1):15-20
15. Parke J, Charles BG (1998) NONMEM population pharmacokinetic modeling of orally administered cyclosporine from routine drug monitoring data after heart transplantation. Ther Drug Monit 20(3):284-293
16. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R (1991) Cyclosporine and methylprednisolone after allogeneic marrow transplantation: Association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transpl 7(6):461-465
17. Rosenbaum SE, Baheti G, Trull AK, Akhlaghi F (2005) Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients. Ther Drug Monit 27(2):116-122
18. Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squares. J Pharmacokinet Biopharm 13(2):185-201
19. Sheiner LB, Rosenberg B, Marathe W (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5(5):445-479
20. Sun B, Li XY, Gao JW, Rui JZ, Guo YK, Peng ZH, Liu GL (2010) Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplant recipients. Ther Drug Monit 32(6):715-722
21. Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J, Vossen JM (2008) Ciclosporin kinetics in children after stem cell transplantation. Br J Clin Pharmacol 66(4):539-545
22. Wu KH, Cui YM, Guo JF, Zhou Y, Zhai SD, Cui FD, Lu W (2005) Population pharmacokinetics of cyclosporine in clinical renal transplant patients. Drug Metab Dispos 33(9):1268-1275
23. Yin OQP, Lau SK, Chow MSS (2006) Population pharmacokinetics of cyclosporine in Chinese cardiac transplant recipients. Pharmacotherapy 26(6):790-797